Editorial
The Future of Biological Therapies in COPD
Futuro de los tratamientos biológicos en la EPOC
Joaquim Gea
Servicio de Neumología, Hospital del Mar. IMIM. DCEXS, Universitat Pompeu Fabra, CIBERES, ISCIII, Barcelona, Spain
Read
6463
Timeswas read the article
2146
Total PDF
4317
Total HTML
Share statistics
array:24 [ "pii" => "S1579212918300430" "issn" => "15792129" "doi" => "10.1016/j.arbr.2018.02.013" "estado" => "S300" "fechaPublicacion" => "2018-04-01" "aid" => "1774" "copyright" => "SEPAR" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2018;54:185-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1618 "formatos" => array:3 [ "EPUB" => 195 "HTML" => 982 "PDF" => 441 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0300289617304210" "issn" => "03002896" "doi" => "10.1016/j.arbres.2017.11.004" "estado" => "S300" "fechaPublicacion" => "2018-04-01" "aid" => "1774" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2018;54:185-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3769 "formatos" => array:3 [ "EPUB" => 208 "HTML" => 2395 "PDF" => 1166 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Futuro de los tratamientos biológicos en la EPOC" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "185" "paginaFinal" => "186" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "The Future of Biological Therapies in COPD" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Joaquim Gea" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Joaquim" "apellidos" => "Gea" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1579212918300430" "doi" => "10.1016/j.arbr.2018.02.013" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212918300430?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289617304210?idApp=UINPBA00003Z" "url" => "/03002896/0000005400000004/v2_201804150418/S0300289617304210/v2_201804150418/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1579212918300454" "issn" => "15792129" "doi" => "10.1016/j.arbr.2017.11.016" "estado" => "S300" "fechaPublicacion" => "2018-04-01" "aid" => "1793" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2018;54:187-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1551 "formatos" => array:3 [ "EPUB" => 152 "HTML" => 950 "PDF" => 449 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Neutrophilic Asthma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "187" "paginaFinal" => "188" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Asma neutrofílica" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ian M. Adcock, Sharon E. Mumby" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Ian M." "apellidos" => "Adcock" ] 1 => array:2 [ "nombre" => "Sharon E." "apellidos" => "Mumby" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0300289617304441" "doi" => "10.1016/j.arbres.2017.11.018" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289617304441?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212918300454?idApp=UINPBA00003Z" "url" => "/15792129/0000005400000004/v2_201804150412/S1579212918300454/v2_201804150412/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1579212918300429" "issn" => "15792129" "doi" => "10.1016/j.arbr.2018.02.012" "estado" => "S300" "fechaPublicacion" => "2018-04-01" "aid" => "1772" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2018;54:183-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1092 "formatos" => array:3 [ "EPUB" => 134 "HTML" => 634 "PDF" => 324 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Hybrid Procedures for Pulmonary Nodule Resection: The Beginning of a New Era" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "183" "paginaFinal" => "184" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Procedimientos híbridos para la resección de nódulos pulmonares: el comienzo de una nueva era" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Andrés Obeso, Hicham Abada, Redha Souilamas" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Andrés" "apellidos" => "Obeso" ] 1 => array:2 [ "nombre" => "Hicham" "apellidos" => "Abada" ] 2 => array:2 [ "nombre" => "Redha" "apellidos" => "Souilamas" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0300289617304192" "doi" => "10.1016/j.arbres.2017.11.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289617304192?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212918300429?idApp=UINPBA00003Z" "url" => "/15792129/0000005400000004/v2_201804150412/S1579212918300429/v2_201804150412/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "The Future of Biological Therapies in COPD" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "185" "paginaFinal" => "186" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Joaquim Gea" "autores" => array:1 [ 0 => array:3 [ "nombre" => "Joaquim" "apellidos" => "Gea" "email" => array:1 [ 0 => "quim.gea@upf.edu" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Neumología, Hospital del Mar. IMIM. DCEXS, Universitat Pompeu Fabra, CIBERES, ISCIII, Barcelona, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Futuro de los tratamientos biológicos en la EPOC" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">In recent years new treatments that go further than conventional therapeutical approaches (i.e. bronchodilators and classical antoinflammatory drugs) have been developed for COPD. Bronchodilators are used to try to increase the size of the airway and improve symptoms, while anti-inflammatories, mainly corticosteroids and phosphodiesterase 4 (PDE4) inhibitors, are aimed at reducing inflammation, one of the most significant pathogenic mechanisms in COPD. The new treatments, called “biologics” or “biological response modifiers” (BRM), act by neutralizing or modulating the function of certain molecular targets, and thus have a more specific anti-inflammatory action. To date, they have been developed and used mainly in bronchial asthma and lung cancer, but they are now also appearing on the horizon for the treatment of COPD.</p><p id="par0010" class="elsevierStylePara elsevierViewall">We know that in COPD, the airway develops an inflammatory response to various noxious stimuli (tobacco smoke, particles/gases, microorganisms), which by activating Toll-like receptors (TLRs), cause the recruitment of multiple immune system cells (predominantly neutrophils) and the secretion of inflammatory mediators.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">1</span></a> The typical immunological response in COPD is thought to be mediated mainly by the helper and cytotoxic T cell subsets (Th1/Tc2).<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">2</span></a> In the case of asthma-COPD overlap (ACO), other co-activating noxious stimuli, such as allergens, are probably involved, with eosinophils playing an active role in this response. The most important inflammatory mediators include cytokines, chemokines and growth factors, those most probably involved in COPD being tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-8, IL-13, IL-18, IL-23, IL-33, eotaxin (CCL)-1, thymic stromal lymphopoietin (TSLP), and transforming growth factor (TGF)-β.<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">1,3,4</span></a> Most biological therapies are based on the administration of antibodies against these mediators or their receptors, although inhibitors, mostly of kinases, are also used; and it seems likely that in the near future even modulators of the pulmonary microbiota will be added to the range of available biological treatments.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Antibodies have numerous advantages. They are very specific and show strong affinity for the antigen; they are also metabolically stable, and do not produce toxic metabolites. These compounds are currently either “humanized” or fully human in order to avoid immunogenicity problems. Some can act on two targets simultaneously (bi-specific). They can be used separately or as an adjunct to conventional treatment, and while administration is mainly parenteral, the inhalatory route is being trialed with relative success. The disadvantages of the therapeutic use of antibodies include high costs, that will probably fall in the future, and the possibility of undesirable side effects.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Several antibodies are currently in development or already available on the market, the most important being those directed against TNFα and IL-β, or their respective receptors.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">4</span></a> Some have already been tested in COPD and have shown disappointing results and/or significant adverse effects (e.g., etanercept, infliximab, and canakinumab),<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">5–8</span></a> while the effects of others have not yet been determined in this patient group (e.g., adalimumab, certolizumab, gevokizumab, anakinra o rilonacept).<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">4,8</span></a> The anti-IL-8 antibody, ABX-CXCL8, has been seen to slightly reduce dyspnea, but the effects on pulmonary function and exacerbations were negligible.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">9</span></a> No studies in COPD patients have been published to date with antibodies directed against IL-6 (e.g., sirukumab, olokizumab sirukumab, and tocilizumab), TGF-β (e.g., metelimumab and resolimumab), IL-33 (e.g., AMG282), or the IL-4/IL-13 (e.g., pascolizumab) and IL-17/IL-23 (e.g., ustekinumab) signaling axis.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">4,5,8,10</span></a> The only exception is the anti-IL-17 antibody, CNTO6785, which however failed to show benefits in this disease.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">11</span></a> It is also interesting to see that some treatments with clear beneficial effects in asthma have also been tested in the ACO phenotype. This includes benralizumab, an anti-IL-5 antibody, that has provided slight functional improvement in this phenotype.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">12</span></a> In contrast, anti-IgE, anti-CCL-11 and anti-TSLP drugs have shown no clinical improvements in patients with ACO.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">10</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Inflammatory mediators are regulated by various kinases which act via transcription factors, such as the kappa-light-chain-enhancer of activated B-cells (NFκ-B) and activator protein-1 (AP1). A second therapeutic approach for biologics is inhibition of these molecules. This pathway is being actively investigated, and is already widely used in other diseases. The great disadvantages of this approach are its low specificity, the frequent development of resistance, and the possibility of serious adverse effects. Unfortunately, kinase κB inhibitors (IKK) have so far either produced side effects that are unacceptable to COPD patients (e.g., IMD-1041), or have not yet been tested in this disease (e.g., IMD-0354 and TPCA-1).<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">5–7</span></a> Inhaled anti-IKK drugs, a route that may reduce adverse effects, are currently under development (e.g., PF104). P38 mitogen-activated protein kinases (MAPK) inhibitors may also be used. Some have already been used with relative success in COPD: for example, SB-681323 (that reduces the release of cytokines in the airway), PH-797804 (that can reduce symptoms and improve lung function), losmapimod (that improves lung function and reduces exacerbations), or inhaled RV-568 (that also seems to improve respiratory function).<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">5–7,13,14</span></a> Finally, the possibility exists of inhibiting other kinases, such as c-Jun NH2-terminal kinases (JUN NH2) (e.g., SP-600125, already tested in asthma), or extracellular signal-regulated kinases (ERK 1 and 2) (e.g., macrolides, trametinib and genistein), apoptotic signal-regulating kinases (ASK1) (e.g., thioredoxin and GS-4997), TGF-β activated kinase (TAK1) (e.g., 5Z-7-oxozeaenol), and calmodulin-dependent kinase (MK2). The effects of these compounds in COPD patients are still unknown, but promising results have emerged from ex vivo studies,<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">15</span></a> and several clinical studies are already planned.</p><p id="par0030" class="elsevierStylePara elsevierViewall">One possible reason for the lack of more conclusive results with many of the current biologics is that the patients included in many of the trials are inadequately phenotyped or endotyped. It is logical to assume that in such a heterogeneous disease as COPD, the molecular targets will not be the same in all patients. Furthermore, it is important to remember that inflammation is not the only biological process involved in the development and progress of the disease.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Finally, there are other avenues for possible new biological modulation, such as regulation of the pulmonary microbiota or the expression of certain genes involved in the development of COPD, since our knowledge on their function is still very limited, and go beyond the scope of this editorial.</p><p id="par0040" class="elsevierStylePara elsevierViewall">In summary, the typical pulmonary and systemic inflammatory response in COPD may be modulated with the use of biological treatments, which already goes further than corticosteroids and PDE4 inhibitors. These treatments are based primarily on the administration of antibodies against inflammatory mediators or inhibitors of various kinases and/or transcription factors. Most biologics are still in the investigational phase, and some have already shown interesting results, although in some cases these results are offset by significant undesirable effects, that could be reduced if the drug is administred by inhalation.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Funding</span><p id="par0045" class="elsevierStylePara elsevierViewall">Partially funded by SAF2011-26908 (FEDER funds), SAF2014-54371 (FEDER funds) and SEPAR 2015.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Funding" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Gea J. Futuro de los tratamientos biológicos en la EPOC. Arch Bronconeumol. 2018;54:185–186.</p>" ] ] "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0055" class="elsevierStylePara elsevierViewall"><elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>" "etiqueta" => "Appendix" "titulo" => "Supplementary data" "identificador" => "sec0015" ] ] ] ] "multimedia" => array:1 [ 0 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.mp3" "ficheroTamanyo" => 12665852 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib0080" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.F. Vogelmeier" 1 => "G.J. Criner" 2 => "F.J. Martínez" 3 => "A. Anzueto" 4 => "P.J. Barnes" 5 => "J. Bourbeau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arbres.2017.02.001" "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2017" "volumen" => "53" "paginaInicial" => "128" "paginaFinal" => "149" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28274597" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0085" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consensus on the asthma-COPD overlap syndrome (ACOS) between the Spanish COPD guidelines (GesEPOC) and the Spanish guidelines on the management of asthma (GEMA)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "V. Plaza" 1 => "F. Álvarez" 2 => "M. Calle" 3 => "C. Casanova" 4 => "B.G. Cosío" 5 => "A. López-Viña" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arbres.2017.04.002" "Revista" => array:6 [ "tituloSerie" => "Arch Bronconeumol" "fecha" => "2017" "volumen" => "53" "paginaInicial" => "443" "paginaFinal" => "449" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28495077" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0090" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cellular and molecular mechanisms of asthma and COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "P.J. Barnes" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Sci (Lond)" "fecha" => "2017" "volumen" => "131" "paginaInicial" => "1541" "paginaFinal" => "1558" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0095" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Therapeutic monoclonal antibodies for the treatment of chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.G. Matera" 1 => "C. Page" 2 => "P. Rogliani" 3 => "L. Calzetta" 4 => "M. Cazzola" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s40265-016-0625-9" "Revista" => array:6 [ "tituloSerie" => "Drugs" "fecha" => "2016" "volumen" => "76" "paginaInicial" => "1257" "paginaFinal" => "1270" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27506851" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0100" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Emerging anti-inflammatory strategies for COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Cazzola" 1 => "C.P. Page" 2 => "L. Calzetta" 3 => "M.G. Matera" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/09031936.00213711" "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "2012" "volumen" => "40" "paginaInicial" => "724" "paginaFinal" => "741" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22496331" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0105" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "P.J. Barnes" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1124/pr.116.012518" "Revista" => array:6 [ "tituloSerie" => "Pharmacol Rev" "fecha" => "2016" "volumen" => "68" "paginaInicial" => "788" "paginaFinal" => "815" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27363440" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0110" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Banerjee" 1 => "C. Koziol-White" 2 => "R. Panettieri Jr." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.coph.2012.01.016" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Pharmacol" "fecha" => "2012" "volumen" => "12" "paginaInicial" => "287" "paginaFinal" => "292" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22365729" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0115" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cytokine inhibition in the treatment of COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "G. Caramori" 1 => "I.M. Adcock" 2 => "A. Di Stefano" 3 => "K.F. Chung" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2147/COPD.S42544" "Revista" => array:6 [ "tituloSerie" => "Int J Chron Obstruct Pulmon Dis" "fecha" => "2014" "volumen" => "9" "paginaInicial" => "397" "paginaFinal" => "412" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24812504" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0120" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D.A. Mahler" 1 => "S. Huang" 2 => "M. Tabrizi" 3 => "G.M. Bell" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.126.3.926" "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2004" "volumen" => "126" "paginaInicial" => "926" "paginaFinal" => "934" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15364775" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0125" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Nixon" 1 => "P. Newbold" 2 => "T. Mustelin" 3 => "G.P. Anderson" 4 => "R. Kolbeck" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.pharmthera.2016.10.016" "Revista" => array:6 [ "tituloSerie" => "Pharmacol Ther" "fecha" => "2017" "volumen" => "169" "paginaInicial" => "57" "paginaFinal" => "77" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27773786" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0130" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Eich" 1 => "V. Urban" 2 => "M. Jutel" 3 => "J. Vlcek" 4 => "J.J. Shim" 5 => "V.I. Trofimov" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1080/15412555.2017.1335697" "Revista" => array:6 [ "tituloSerie" => "COPD" "fecha" => "2017" "volumen" => "14" "paginaInicial" => "476" "paginaFinal" => "483" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28753067" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0135" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.E. Brightling" 1 => "E.R. Bleecker" 2 => "R.A. Panettieri Jr." 3 => "M. Bafadhel" 4 => "D. She" 5 => "C.K. Ward" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2213-2600(14)70187-0" "Revista" => array:6 [ "tituloSerie" => "Lancet Respir Med" "fecha" => "2014" "volumen" => "2" "paginaInicial" => "891" "paginaFinal" => "901" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25208464" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0140" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.E. Charron" 1 => "P. Russell" 2 => "K. Ito" 3 => "S. Lea" 4 => "Y. Kizawa" 5 => "C. Brindley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/13993003.00188-2017" "Revista" => array:5 [ "tituloSerie" => "Eur Respir J" "fecha" => "2017" "volumen" => "50" "paginaInicial" => "1700188" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29074542" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0145" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "W. MacNee" 1 => "R.J. Allan" 2 => "I. Jones" 3 => "M.C. de Salvo" 4 => "L.F. Tan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/thoraxjnl-2012-202744" "Revista" => array:6 [ "tituloSerie" => "Thorax" "fecha" => "2013" "volumen" => "68" "paginaInicial" => "738" "paginaFinal" => "745" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23539534" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0150" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of resveratrol and genistein on nuclear factor-κB, tumor necrosis factor-α and matrix metalloproteinase-9 in patients with chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "X.J. Liu" 1 => "H.R. Bao" 2 => "X.L. Zeng" 3 => "J.M. Wei" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3892/mmr.2016.5057" "Revista" => array:6 [ "tituloSerie" => "Mol Med Rep" "fecha" => "2016" "volumen" => "13" "paginaInicial" => "4266" "paginaFinal" => "4272" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27035424" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15792129/0000005400000004/v2_201804150412/S1579212918300430/v2_201804150412/en/main.assets" "Apartado" => array:4 [ "identificador" => "46447" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15792129/0000005400000004/v2_201804150412/S1579212918300430/v2_201804150412/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212918300430?idApp=UINPBA00003Z" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 5 | 1 | 6 |
| 2024 October | 57 | 36 | 93 |
| 2024 September | 73 | 28 | 101 |
| 2024 August | 81 | 37 | 118 |
| 2024 July | 41 | 34 | 75 |
| 2024 June | 54 | 37 | 91 |
| 2024 May | 88 | 41 | 129 |
| 2024 April | 55 | 44 | 99 |
| 2024 March | 54 | 23 | 77 |
| 2024 February | 44 | 31 | 75 |
| 2023 April | 6 | 2 | 8 |
| 2023 March | 21 | 6 | 27 |
| 2023 February | 96 | 31 | 127 |
| 2023 January | 77 | 47 | 124 |
| 2022 December | 69 | 40 | 109 |
| 2022 November | 76 | 34 | 110 |
| 2022 October | 77 | 36 | 113 |
| 2022 September | 47 | 24 | 71 |
| 2022 August | 45 | 47 | 92 |
| 2022 July | 47 | 46 | 93 |
| 2022 June | 43 | 37 | 80 |
| 2022 May | 61 | 39 | 100 |
| 2022 April | 76 | 37 | 113 |
| 2022 March | 83 | 42 | 125 |
| 2022 February | 67 | 37 | 104 |
| 2022 January | 61 | 41 | 102 |
| 2021 December | 53 | 50 | 103 |
| 2021 November | 91 | 52 | 143 |
| 2021 October | 97 | 54 | 151 |
| 2021 September | 87 | 54 | 141 |
| 2021 August | 75 | 45 | 120 |
| 2021 July | 55 | 35 | 90 |
| 2021 June | 74 | 63 | 137 |
| 2021 May | 101 | 56 | 157 |
| 2021 April | 168 | 83 | 251 |
| 2021 March | 117 | 32 | 149 |
| 2021 February | 91 | 22 | 113 |
| 2021 January | 79 | 16 | 95 |
| 2020 December | 70 | 24 | 94 |
| 2020 November | 76 | 29 | 105 |
| 2020 October | 90 | 41 | 131 |
| 2020 September | 78 | 36 | 114 |
| 2020 August | 78 | 19 | 97 |
| 2020 July | 85 | 28 | 113 |
| 2020 June | 68 | 17 | 85 |
| 2020 May | 64 | 21 | 85 |
| 2020 April | 59 | 30 | 89 |
| 2020 March | 49 | 17 | 66 |
| 2020 February | 80 | 41 | 121 |
| 2020 January | 55 | 19 | 74 |
| 2019 December | 86 | 24 | 110 |
| 2019 November | 62 | 32 | 94 |
| 2019 October | 64 | 16 | 80 |
| 2019 September | 70 | 24 | 94 |
| 2019 August | 63 | 31 | 94 |
| 2019 July | 41 | 29 | 70 |
| 2019 June | 47 | 24 | 71 |
| 2019 May | 44 | 17 | 61 |
| 2019 April | 79 | 29 | 108 |
| 2019 March | 59 | 34 | 93 |
| 2019 February | 47 | 31 | 78 |
| 2019 January | 50 | 20 | 70 |
| 2018 December | 53 | 29 | 82 |
| 2018 November | 50 | 33 | 83 |
| 2018 October | 50 | 29 | 79 |
| 2018 September | 5 | 1 | 6 |
| 2018 May | 1 | 0 | 1 |
| 2018 April | 2 | 1 | 3 |
Show all
